IMPACT OF BASELINE MODIFIED RHEUMATIC DISEASE COMORBIDITY INDEX (MRDCI) ON DRUG SURVIVAL AND EFFECTIVENESS OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED WITH RHEUMATOID ARTHRITIS (RA), SPONDYLOARTHRITIS (SPA), AND PSORIATIC ARTHRITIS (PSA) IN REAL-WORLD SETTINGS